Xgeva Prostate Cancer Claim May Not Benefit Beyond Existing Cancer Indication, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will ask the Oncologic Drugs Advisory Committee whether delaying bone metastases in high-risk castrate-resistant prostate cancer patients provides benefit above that obtained with current use of t drug to delay skeletal-related events and is worth a potentially higher risk for osteonecrosis of the jaw.